Nanoligent
Nanoligent aim is the research and development to clinical phases of innovative cancer treatments based on protein nanoparticles.
Nanoligent has raised €13M across 2 funding rounds from 6 investors, most recently a round in Oct 2025. Based in Barcelona, Spain; active in Healthtech. Data as of 28 Oct 2026.
Barcelona, Spainwww.nanoligent.com ↗
Total raised
€13M
€13,000,000
Funding rounds
2
Investors
6
distinct backers
Active since
2022-02
latest 2025-10
Funding by year
EUR raised per yearNanoligent — funding by year — interactive chart.
Data table
| Nanoligent — funding by year | |
|---|---|
| 2022 | €1.0M |
| 2025 | €12M |
Signals
High confidenceRaise-next likelihood46
base rate 30% for Other
- ▲ In typical raise window
- ▲ Up-round momentum
- ▼ Low backer re-investment
Exit likelihood15
base rate 11% (2+ rounds)
- ▲ Recently backed by strong-exit-track investors
Timing: in window vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2025-10-10 | Other | €12M | Biotech IV fund,CDTI,Clave Capital,Inveready | View deal → |
| 2022-02-04 | Other | €1.0M | AVANTECA Partners,Italian Angels for Growth (IAG) | View deal → |
Related news
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- CMR Surgical€1.5BUK · Healthtech
- Jobandtalent€1.4BSpain · HRtech
- Roivant Sciences€1.1BSwitzerland · Healthtech
- Perk (formerly TravelPerk)€1.1BSpain · Travel
Global coverage: FundingData